PhaseⅠstudy of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma
Latest Information Update: 20 Jul 2021
At a glance
- Drugs AL 2846 (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 20 Jul 2021 New trial record
- 08 Jun 2021 Results (n=15; as of 1 Jan 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.